Brokerages Set Aptose Biosciences Inc. (NASDAQ:APTO) Price Target at $14.80

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) has earned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $14.80.

APTO has been the topic of a number of research reports. Canaccord Genuity Group dropped their price objective on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. StockNews.com initiated coverage on Aptose Biosciences in a report on Sunday. They set a “hold” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Aptose Biosciences in a report on Friday, June 14th.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $0.40 on Tuesday. The stock’s 50 day moving average price is $0.63 and its 200 day moving average price is $1.14. Aptose Biosciences has a 52 week low of $0.39 and a 52 week high of $4.26. The company has a market capitalization of $7.26 million, a P/E ratio of -0.06 and a beta of 1.27.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.15. As a group, sell-side analysts forecast that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.